Allegro's microparticle hydrogel hydrocelin has the potential to be a first-in-class disease-modifying injectable treatment ...

The product is intended to be administered by injection once yearly. In addition to the pyrogenicity study, the company has also found a satisfactory safety record in preclinical studies assessing ...

Allegro’s microparticle hydrogel hydrocelin has the potential to be a first-in-class disease-modifying injectable treatment for osteoarthritis Preclinical study to be presented at WCO conference shows ...